Rx data firms sue Maine, Vermont

Share this article:
Three firms are challenging Maine and Vermont over new state laws that restrict the collection and disclosure of physician prescribing information.

IMS Health, Wolters Kluwer Health and Verispan want to prevent statutes in the two states from taking effect Jan. 1.

A similar New Hampshire law that would have limited drug company access to doctors' prescribing habits was struck down in U.S. District Court in April on constitutional grounds.

The suits, filed today, say the Maine and Vermont statutes differ only slightly from the New Hampshire law and that they deny access to information that is central to improving the quality of care and ensuring patient safety.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...